Announced Fri, 3 Jul · 12:21 IST
Zydus partners with Apollo Hospitals for cancer detection test expansion
Compliance View source PDF
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹1101.60
prior close
₹1128.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.1+0.3+0.5+4.0+4.6+4.1+5.4+4.4+2.9+0.7———
Up moveDown movePending
AI summary
Zydus Lifesciences has signed an MoU with Apollo Hospitals to expand access to its Shield Multi-Cancer Detection (MCD) test across India. The partnership will use Apollo's hospital network to make the diagnostic test available to more patients, supporting early cancer detection. This collaboration strengthens Zydus's presence in the diagnostics segment.
Likely market impact
Expands reach of cancer detection test via Apollo's hospital network, potentially boosting Zydus diagnostic revenue. Positive for growth story.